Zimbabwe has declined a major American health deal worth 367 million US dollars (£272m) over five years over Washington's request for sensitive data.
This move became public following a official document from December was leaked, revealing that Head of State Emmerson Mnangagwa felt the agreement was "unbalanced".
An official spokesperson later clarified that the US was requesting biological samples for scientific study and commercial gain but was not willing to share the resulting advantages from any future medical innovations.
"We must now begin the challenging and unfortunate process of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had donated over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for more dialogue to secure a agreement acceptable to all parties so the country's vital HIV programme can continue.
Wider Context
This rejection comes after a similar case in neighbouring Kenya, where a court blocked a related health funding agreement after legal challenges were raised about the security of Kenyans' health data.
After resuming office recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump stated its expenditure was "wasteful" and his government was seeking direct bilateral agreements to boost openness and responsibility.
Based on statements, 16 African countries have so far agreed to these new agreements, constituting over $18.3bn of fresh investment.
Specifics of the Declined Agreement
The funds for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership could have provided significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment via US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data over an extended period, with no corresponding promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"Put simply, our nation would supply the raw materials for scientific discovery with no certainty that the final treatments would be accessible to our population should a future pandemic arise."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the global health body and its pursuit of bilateral deals were undermining structures previously set up through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing system created to manage potential global health emergencies.
"This mechanism is designed to guarantee that when a nation contributes its information, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
The government's concerns regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We welcome continued discussions with our US partners on how future co-operation might be arranged in a way that honours the sovereignty and dignity of both nations."
Medical Community Response
Medical experts expressed it understood the official position, but urged that negotiations need to persist considering a large portion of the country's HIV programmes depended on external financing.
"Where technical issues exist, including those involving data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," the group said.
This impasse underscores the complex challenges between accepting crucial international aid and safeguarding a country's data in an ever more data-driven world.